DE-PRESCRIBING MEDICATIONS IN OLDER ADULTS WITH DEMENTIA
Dr Daniel Hoyle
Senior Lecturer, Therapeutics and Pharmacy Practice
School of Pharmacy and Pharmacology,
University of Tasmania, Australia
RESEARCHER PROFILE
Filmed in Hobart, Tasmania, Australia | January 2025
Dr. Daniel Hoyle is a Senior Lecturer in Therapeutics and Pharmacy Practice at the School of Pharmacy and Pharmacology, University of Tasmania. He is also an experienced clinical pharmacist with expertise in medication management in older people. Dr. Hoyle’s research interests focus on improving medicine use in older people with dementia.
He earned his PhD from the University of Tasmania in 2020, where his doctoral research examined the clinical and economic outcomes of psychotropic deprescribing within the multidisciplinary “Reducing Use of Sedatives” project implemented across 150 Australian aged care homes. This research has received several accolades, including First Place in the International Psychogeriatric Association Junior Research Awards in 2019.
Currently, Dr. Hoyle leads several projects, including research aimed at improving anticoagulant use in older individuals with dementia and atrial fibrillation using national primary care provider datasets, and the implementation of a hospital-based antipsychotic stewardship program for patients with dementia and/or delirium.
A current project is Geriatric Antipsychotic Stewardship (GApS) Program for Behavioural and Psychological Symptoms of Dementia and Delirium. This program is funded by the Royal Hobart Hospital Research Foundation through an Incubator Grant.
Additionally, Dr. Hoyle serves as an investigator within an educational intervention aimed at improving anticholinergic prescribing in hospitals. Dr. Hoyle is a guest editor with Pharmacy MDPI and holds elected positions on the Australian Deprescribing Network Executive Committee and the Pharmaceutical Society of Australia’s Tasmanian Branch Committee.
https://orcid.org/0000-0003-2867-3736
-
Investigating the benefits of donor human milk for preterm infants
Together, SAHMRI and Lifeblood are leading a consortium to revolutionise the way human milk, and novel products made from human milk, are used as nutritional and medical interventions to improve health outcomes in vulnerable infants, but with potential application for a diverse range of medical indications.
Currently, babies who are born early preterm – before 32 weeks – are given donor milk when their own mother’s milk is not available or in short supply. Whether donor milk is beneficial for babies born just a few weeks early is unclear, as very little research has been undertaken with these babies.
The GIFT Trial will soon commence as an investigation between SAHMRI, the University of Adelaide, the Red Cross Lifeblood Milk Bank conducted at five sites across three states in Australia.
-
Patient reported outcomes in the diagnosis and treatment of lymphoma
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
-
Professor Kim Hemsley
RESEARCH IN BRAIN COMPUTER INTERFACE
@ SYNCHRON
MELBOURNE, VICTORIA, AUSTRALIA
